Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
| ▸ | IL1RN | P18510 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676320 | 0.80 | ALDH1A1 (0.55) | PKMALDH1A1MAPTIDH1CA1 | |
| SCHEMBL6675225 | 0.80 | LMNA (0.56) | ALDH1A1MEN1KMT2AMAPTCA1 | |
| SCHEMBL7163015 | 0.78 | ALDH1A1 (0.68) | PTK2BIL1RNKEAP1ERAP1PKM | |
| SCHEMBL17609451 | 0.76 | PTK2B (0.55) | PTK2BIL1RNKEAP1ERAP1PKM | |
| SCHEMBL6073362 | 0.76 | CA1 (0.62) | PTK2BIL1RNKEAP1ERAP1PKM | |
| SCHEMBL7627388 | 0.75 | KEAP1 (0.67) | PTK2BIL1RNKEAP1ERAP1PKM | |
| SCHEMBL27561521 | 0.75 | ALPL (0.69) | PTK2BTET2ALDH1A1IDH1 | |
| SCHEMBL6678841 | 0.74 | SMN1; SMN2 (0.52) | PKMALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL29671250 | 0.74 | SMN1; SMN2 (0.52) | PKMALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL6677115 | 0.74 | SMN1; SMN2 (0.60) | PKMALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060718-B2 | Arylsulfonanilide ureas | AMGEN INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20030207864-A1 | Arylsulfonanilide ureas | TULARK INC. | 2003-11-06 | — | — | US | disclosed |
| US-6583165-B2 | Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1115701-B1 | ARYLSULFONANILIDE UREAS | TULARIK INC (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1285911-A2 | Arylsulfonanilide ureas | Tularik Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20010027211-A1 | Arylsulfonanilide ureas | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| EP-1115701-A1 | ARYLSULFONANILIDE UREAS | Tularik Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6214880-B1 | LOWERING PLASMA CHOLESTEROL LEVELS AND INHIBITING ABNORMAL CELL PROLIFERATION WITH SAID COMPOUND; TREATMENT OF CANCER, PSORIASIS, VASCULAR RESTENOSIS, INFECTIONS, ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. | 2001-04-10 | — | — | US | disclosed |
| WO-2000017159-A1 | ARYLSULFONANILIDE UREAS | TULARIK INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207864-A1 | Arylsulfonanilide ureas | UTS2R, UACA, UMPS | PTK2B 1608/4885IL1RN 1457/4885KEAP1 887/4885 |
| US-20010027211-A1 | Arylsulfonanilide ureas | UTS2R, UACA, UMPS | PTK2B 1608/4885IL1RN 1457/4885KEAP1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.